Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group.
Martin FennerChristoph OingAnnette DieingThomas GaulerKarin OechsleAnja LorchMarcus HentrichHans-Georg KoppCarsten BokemeyerFriedemann HoneckerPublished in: Journal of cancer research and clinical oncology (2018)
Targeting the mTOR pathway with single-agent everolimus failed to produce clinically relevant responses in pts with heavily pretreated and/or cisplatin-refractory GCC.
Keyphrases
- phase ii
- open label
- germ cell
- clinical trial
- phase iii
- double blind
- phase ii study
- study protocol
- placebo controlled
- acute lymphoblastic leukemia
- acute myeloid leukemia
- papillary thyroid
- multiple myeloma
- cross sectional
- randomized controlled trial
- diffuse large b cell lymphoma
- squamous cell
- squamous cell carcinoma
- cancer therapy
- hodgkin lymphoma
- cell proliferation
- drug delivery
- rectal cancer